News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>HSBC Research Adds CMS (00867.HK) TP to $17, Keeps Buy Rating
CMS (00867.HK) launched its Ruxolitinib cream in China, making it the first and only approved targeted drug for treating vitiligo, HSBC Global Research published a research report ...
Reset
Send
The window will close in 5 seconds
<Research>HSBC Research Adds CMS (00867.HK) TP to $17, Keeps Buy Rating
Close
Recommend
3
Positive
5
Negative
1
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

CMS (00867.HK)  +0.500 (+3.615%)    Short selling $13.79M; Ratio 70.360%   launched its Ruxolitinib cream in China, making it the first and only approved targeted drug for treating vitiligo, HSBC Global Research published a research report saying.

Ruxolitinib has shown excellent efficacy. Therefore, the broker expected its 2026 sales to reach RMB500 million and double in 2027. HSBC Global Research kept rating at Buy, and added its target price from $16.8 to $17.

CMS announced that its subsidiary Dermavon received approval to launch Ruxolitinib phosphate cream in China for treating non-segmental vitiligo for teenagers over 12 years old and adult patients.

Ruxolitinib was initially developed by Incyte, with global sales of its oral and cream versions reaching US$2.8 billion and US$500 million each in 2024, representing a YoY growth of 8% and 50%. The drug is the first and only approved targeted treatment for vitiligo in China, targeting approx. 8.2 million patients.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.